Ambit Biosciences has entered a screening, discovery and development collaboration with Cephalon, Inc. aimed at establishing best-in-class kinase inhibitors as candidates for clinical research. By combining Ambit’s KinomeScan-driven discovery capabilities with Cephalon’s chemistry, discovery and development capabilities, the two companies expect to discover and develop small molecule pharmaceutical products in significantly less time. Kinases consist of more than 500 related enz...